Oxidative stress, AGE, and atherosclerosis

Kidney International

Volumn 72, Issue SUPPL. 106, 2007, Pages

  Schleicher, E ^a   Friess, U ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Atherogenesis; Cytokine; Endothelial dysfunction; Glycation endproducts (AGE); NAD(P)H oxidase; Reactive oxygen species (ROS)

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; APOCYNIN; ASCORBIC ACID; BIOLOGICAL MARKER; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; GLUCOSE; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROBUCOL; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RUBOXISTAURIN; THIOCTIC ACID; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; FATTY ACID BLOOD LEVEL; GENE EXPRESSION; GENE INDUCTION; GLOMERULONEPHRITIS; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; HYPERTENSION; MITOCHONDRION; MYOCARDIAL DISEASE; NEUROTOXICITY; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RESTENOSIS; ANIMAL; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; BLOOD GLUCOSE; CYTOKINES; ENDOTHELIUM, VASCULAR; FATTY ACIDS, NONESTERIFIED; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MICE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 34547447707     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002382     Document Type: Conference Paper

References (86)

1. Uusitupa MI, Niskanen LK, Siitonen O et al. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 1990; 82: 27-36.
2. Stocker R, Keaney Jr JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-1478.
3. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973; 180: 1332-1339.
4. Steinberg D, Parthasarathy S, Carew TE et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924.
5. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.
6. Balletshofer BM, Rittig K, Enderle MD et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101: 1780-1784.
7. Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
8. Ceriello A. Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes. Curr Opin Lipidol 2006; 17: 510-518.
9. Johansen JS, Harris AK, Rychly DJ et al. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 2005; 4: 5-16.
10. Sies H. Oxidative stress: from basic research to clinical application. Am J Med 1991; 91: 31S-38S.
11. Maxwell SR, Thomason H, Sandler D et al. Poor glycaemic control is associated with reduced serum free radical scavenging (antioxidant) activity in non-insulin-dependent diabetes mellitus. Ann Clin Biochem 1997; 34: 638-644.
12. Waddington EI, Croft KD, Sienuarine K et al. Fatty acid oxidation products in human atherosclerotic plaque: an analysis of clinical and histopathological correlates. Atherosclerosis 2003; 167: 111-120.
13. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999; 344: 109-116.
14. Hammes HP, Hoerauf H, Alt A et al. N(epsilon)(carboxymethyl)lysin and the AGE receptor RAGE colocalize in age-related macular degeneration. Invest Ophthalmol Vis Sci 1999; 40: 1855-1859.
15. Horiuchi S, Sano H, Higashi T et al. Extra- and intracellular localization of advanced glycation end-products in human atherosclerotic lesions. Nephrol Dial Transplant 1996; 11(Suppl 5): 81-86.
16. Nerlich AG, Schleicher ED. N(epsilon)-(carboxymethyl)lysine in atherosclerotic vascular lesions as a marker for local oxidative stress. Atherosclerosis 1999; 144: 41-47.
17. Sakata N, Imanaga Y, Meng J et al. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis 1998; 141: 61-75.
18. Onorato JM, Thorpe SR, Baynes JW. Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann N Y Acad Sci 1998; 854: 277-290. 277-290.
19. Panzenbock U, Stocker R. Formation of methionine sulfoxide-containing specific forms of oxidized high-density lipoproteins. Biochim Biophys Acta 2005; 1703: 171-181.
20. Reddy S, Bichler J, Wells-Knecht KJ et al. N epsilon- (carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995; 34: 10872-10878.
21. Li H, Nakamura S, Miyazaki S et al. N2-carboxyethyl-2′- deoxyguanosine, a DNA glycation marker, in kidneys and aortas of diabetic and uremic patients. Kidney Int 2006; 69: 388-392.
22. Wautier MP, Chappey O, Corda S et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280: E685-E694.
23. Basta G, Lazzerini G, Del Turco S et al. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol 2005; 25: 1401-1407.
24. Nishikawa T, Edelstein D, Du XL et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-790.
25. Giardino I, Edelstein D, Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest 1996; 97: 1422-1428.
26. Christ M, Bauersachs J, Liebetrau C et al. Glucose increases endothelialdependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin. Diabetes 2002; 51: 2648-2652.
27. Tsubouchi H, Inoguchi T, Sonta T et al. Statin attenuates high glucoseinduced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radic Biol Med 2005; 39: 444-452.
28. Yano M, Hasegawa G, Ishii M et al. Short-term exposure of high glucose concentration induces generation of reactive oxygen species in endothelial cells: implication for the oxidative stress associated with postprandial hyperglycemia. Redox Rep 2004; 9: 111-116.
29. Chinen I, Shimabukuro M, Yamakawa K et al. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology 2007; 148: 160-165.
30. Inoguchi T, Li P, Umeda F et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C - dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49: 1939-1945.
31. Bellin C, de Wiza DH, Wiernsperger NF et al. Generation of reactive oxygen species by endothelial and smooth muscle cells: influence of hyperglycemia and metformin. Horm Metab Res 2006; 38: 732-739.
32. Horani MH, Haas MJ, Mooradian AD. Saturated, unsaturated, and transfatty acids modulate oxidative burst induced by high dextrose in human umbilical vein endothelial cells. Nutrition 2006; 22: 123-127.
33. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
34. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 2003; 108: 1912-1916.
35. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56: 45-62.
36. Staiger H, Staiger K, Stefan N et al. Palmitate-induced interleukin-6 expression in human coronary artery endothelial cells. Diabetes 2004; 53: 3209-3216.
37. Staiger K, Staiger H, Weigert C et al. Saturated, but not unsaturated, fatty acids induce apoptosis of human coronary artery endothelial cells via nuclear factor-kappaB activation. Diabetes 2006; 55: 3121-3126.
38. Weigert C, Brodbeck K, Staiger H et al. Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteasome-dependent activation of nuclear factor-kappaB. J Biol Chem 2004; 279: 23942-23952.
39. Borradaile NM, Han X, Harp JD et al. Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J Lipid Res 2006; 47: 2726-2737.
40. Listenberger LL, Han X, Lewis SE et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 2003; 100: 3077-3082.
41. Bouche C, Serdy S, Kahn CR et al. The cellular fate of glucose and its relevance in type 2 diabetes. Endocr Rev 2004; 25: 807-830.
42. Lee HB, Yu MR, Yang Y et al. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 2003; 14: S241-S245.
43. Rhee SG. Cell signaling. H2O2, a necessary evil for cell signaling. Science 2006; 312: 1882-1883.
44. Goldin A, Beckman JA, Schmidt AM et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605.
45. Gempel KE, Gerbitz KD, Olgemoller B et al. In-Vitro Carboxymethylation of Low Density Lipoprotein Alters its Metabolism via the High-Affinity Receptor. Horm Metab Res 1993; 25: 250-252.
46. Haitoglou CS, Tsilibary EC, Brownlee M et al. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/ type IV collagen. J Biol Chem 1992; 267: 12404-12407.
47. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999; 85: 753-766.
48. Schleicher ED, Gerbitz KD, Dolhofer R et al. Clinical utility of nonenzymatically glycosylated blood proteins as an index of glucose control. Diabetes Care 1984; 7: 548-556.
49. Schleicher E, Deufel T, Wieland OH. Non-enzymatic glycosylation of human serum lipoproteins. Elevated epsilon-lysine glycosylated low density lipoprotein in diabetic patients. FEBS Lett 1981; 129: 1-4.
50. Schleicher E, Wieland OH. Kinetic analysis of glycation as a tool for assessing the half-life of proteins. Biochim Biophys Acta 1986; 884: 199-205.
51. Schleicher ED, Olgemoller B, Wiedenmann E et al. Specific glycation of albumin depends on its half-life. Clin Chem 1993; 39: 625-628.
52. Vogt BW, Schleicher ED, Wieland OH. epsilon-Amino-lysine-bound glucose in human tissues obtained at autopsy. Increase in diabetes mellitus. Diabetes 1982; 31: 1123-1127.
53. Ahmed MU, Brinkmann FE, Degenhardt TP et al. N-epsilon- (carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 1997; 324: 565-570.
54. Schleicher E, Olgemoller B, Schon J et al. Limited nonenzymatic glucosylation of low-density lipoprotein does not alter its catabolism in tissue culture. Biochim Biophys Acta 1985; 846: 226-233.
55. Pongor S, Ulrich PC, Bencsath FA et al. Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc Natl Acad Sci U S A 1984; 81: 2684-2688.
56. Thornalley PJ, Battah S, Ahmed N et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003; 375: 581-592.
57. Januszewski AS, Alderson NL, Metz TO et al. Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans 2003; 31: 1413-1416.
58. Phillips SA, Thornalley PJ. Formation of methylglyoxal and D-lactate in human red blood cells in vitro. Biochem Soc Trans 1993; 21: 163S.
59. Thorpe SR, Baynes JW. Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 1996; 9: 69-77.
60. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2001; 251: 87-101.
61. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 1994; 94: 110-117.
62. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99: 457-468.
63. Schalkwijk CG, Baidoshvili A, Stehouwer CD et al. Increased accumulation of the glycoxidation product Nepsilon-(carboxymethyl)lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. Biochim Biophys Acta 2004; 1636: 82-89.
64. Bierhaus A, Humpert PM, Morcos M et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005; 83: 876-886.
65. Schmidt AM, Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2000; 2: 430-436.
66. Schmidt AM, Vianna M, Gerlach M et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267: 14987-14997.
67. Bierhaus A, Illmer T, Kasper M et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997; 96: 2262-2271.
68. Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4: 1025-1031.
69. Bucciarelli LG, Wendt T, Qu W et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106: 2827-2835.
70. Kislinger T, Tanji N, Wendt T et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001; 21: 905-910.
71. Wendt TM, Tanji N, Guo J et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162: 1123-1137.
72. Sakaguchi T, Yan SF, Yan SD et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111: 959-972.
73. Naka Y, Bucciarelli LG, Wendt T et al. RAGE axis: Animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol 2004; 24: 1342-1349.
74. Huebschmann AG, Regensteiner JG, Vlassara H et al. Diabetes and advanced glycoxidation end products. Diabetes Care 2006; 29: 1420-1432.
75. Brownlee M, Vlassara H, Kooney A et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-1632.
76. Candido R, Forbes JM, Thomas MC et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92: 785-792.
77. Forbes JM, Thallas V, Thomas MC et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003; 17: 1762-1764.
78. Forbes JM, Yee LT, Thallas V et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004; 53: 1813-1823.
79. Hsich E, Segal BH, Pagano PJ et al. Vascular effects following homozygous disruption of p47(phox) : An essential component of NADPH oxidase. Circulation 2000; 101: 1234-1236.
80. Barry-Lane PA, Patterson C, van der MM et al. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest 2001; 108: 1513-1522.
81. Brennan ML, Anderson MM, Shih DM et al. Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest 2001; 107: 419-430.
82. Juan SH, Lee TS, Tseng KW et al. Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 104: 1519-1525.
83. Tardif JC, Gregoire J, L'allier PL et al. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis 2007. [Epub ahead of print].
84. Wu BJ, Kathir K, Witting PK et al. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J Exp Med 2006; 203: 1117-1127.
85. Madamanchi NR, Hakim ZS, Runge MS. Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes. J Thromb Haemost 2005; 3: 254-267.
86. Jialal I, Devaraj S. Antioxidants and atherosclerosis: don't throw out the baby with the bath water. Circulation 2003; 107: 926-928.